Home › Vertex Submits Supplemental New Drug Application (sNDA) To U.S. Food And Drug Administration For KALYDECO (ivacaftor) Monotherapy For People With Non-G551D Gating Mutations
 

Keywords :   


Vertex Submits Supplemental New Drug Application (sNDA) To U.S. Food And Drug Administration For KALYDECO (ivacaftor) Monotherapy For People With Non-G551D Gating Mutations

2013-10-02 05:50:27| drugdiscoveryonline News Articles

Vertex Pharmaceuticals Incorporated recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of KALYDECOTM (ivacaftor) monotherapy for people with cystic fibrosis (CF) ages 6 and older who have at least one non-G551D gating mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene

Tags: with people food application

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.09Eastern North Pacific Tropical Weather Outlook
28.09Atlantic Tropical Weather Outlook
28.09Post-Tropical Cyclone Helene Public Advisory Number 21
28.09Tropical Storm Joyce Public Advisory Number 5
28.09Summary for Tropical Storm Joyce (AT1/AL112024)
28.09Post-Tropical Cyclone Helene Public Advisory Number 21
28.09Tropical Storm Joyce Forecast Discussion Number 5
28.09Tropical Storm Joyce Wind Speed Probabilities Number 5
More »